Scleromyxoedema: Clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes

Acta Dermato-Venereologica

Volumn 92, Issue 4, 2012, Pages 408-409

  Bidier, Mona ^a   Zschoche, Carolin ^a   Gholam, Patrick ^a   Enk, Alexander H ^a   Hadaschik, Eva N ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN LAMBDA CHAIN; MELPHALAN; PREDNISOLONE; THALIDOMIDE;

ADULT; AGED; BREATHING DISORDER; CASE REPORT; DRUG MEGADOSE; ERYTHEMA; FEMALE; FITNESS; FOLLOW UP; HAIR LOSS; HUMAN; HUMAN TISSUE; IMMUNOELECTROPHORESIS; LETTER; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PAPULE; PARAPROTEINEMIA; PRIORITY JOURNAL; PUVA; RASH; RECURRENT DISEASE; RELAPSE; SCLEROMYXEDEMA; SEROLOGY; SKIN BIOPSY; SKIN INDURATION; SKIN NODULE; ULTRAVIOLET A RADIATION; WRINKLE;

FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SCLEROMYXEDEMA; SKIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863454037     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-1299     Document Type: Letter

References (10)

1. Manousaridis I, Loeser C, Goerdt S, Hassel J. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy. Acta Dermatovenerol Alp Panonica Adriat 2010; 19: 15-19.
2. Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol 1995; 33: 37-43.
3. Rongioletti F, Rebora A. Updated classification of popular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001; 44: 273-281.
4. Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine 2008; 87: 10-20.
5. Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol 2003; 42: 31-35.
6. Righi A, Schiavon F, Jablonska S, Doria A, Blasczyk M, Rondinone R, et al. Intravenous immunoglobulins control scleromyxoedema. Ann Rheum Dis 2002; 61: 59-61.
7. Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 2000; 43: 403-408.
8. Roque Diamantino Fde E, Lopes João AM, Clemente Fidalgo AI, Taveira Lobo Mde L. Treatment of scleromyxedema with intravenous immunoglobulin. Eur J Dermatol 2010; 20: 861-862.
9. Enk A. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol 2009; 19: 90-98.
10. Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009; 60: 595-603.